中国保健食品滋补品市场格局分析及投资风险展望报告2026-2032年 【本文源自：鸿晟信合研究院 内容有省略】 二、大型保健食品滋补品等产品自主研发情况 三、保健食品滋补品企业产业优化与战略调整情况 四、2026-2032年保健食品滋补品行业发展预测分析 第六章 保健食品滋补品销售市场分析 第一节 保健食品滋补品国内营销模式分析 第二节 行业价格竞争方式分析 第三节 保健食品滋补品国内销售渠道分析 第四节 保健食品滋补品行业国际化营销模式分析 第五节 保健食品滋补品重点销售区域分析 第六节 保健食品滋补品内部与外部流通量分析 第七章 保健食品滋补品市场价格及价格走势分析 第一节 保健食品滋补品年度价格变化分析 第二节 保健食品滋补品月度价格变化分析 第三节 保健食品滋补品各厂家价格分析 第四节 保健食品滋补品市场价格驱动因素分析 第五节 2026-2032年我国保健食品滋补品市场价格预测分析 第八章 国内保健食品滋补品行业重点企业分析 第一节 健康元药业集团股份有限公司 一、企业简介 二、产品介绍 三、经营情况 四、未来发展趋势 五、企业优劣势分析 六、企业投资情况调查 七、企业产品特征现状及趋势预测 八、企 ...

近日，受印度疫情影响，A股医药板块再获资金关注。继昨日收涨超1.4%后，今日（1.27）中药ETF（560080）回调近2%，成交额快速突破8500 万元。资金面上，昨日中药ETF（560080）获超3900万元净流入。 消息面上，2026年1月，印度西孟加拉邦及其周边地区疫情再现。已确认5例感染病例，近100人被隔离观察。受此影响，周边国家纷纷提高警惕， 泰国和尼泊尔已相继加强针对来自印度旅客的卫生筛查措施。 近期，中科院武汉病毒所等多团队联合研究取得重要突破，其成果于国际期刊《Emerging Microbes & Infections》发表，证实口服核苷类药物 VV116对尼帕病毒具有显著的抗病毒活性，为这一高致死性新发传染病的防治带来新希望。该成果首次证实VV116对尼帕病毒的治疗潜力，不仅可 作为医护人员、实验室工作者等高危人群的预防性用药，更可为应对当下和未来的尼帕病毒疫情提供了一个现成的药物选择。 近日，《藏医疾病分类与代码》(GB/T46946—2025)推荐性国家标准获批发布。该标准由国家中医药管理局组织起草，将自4月1日起正式实施。该 标准是我国民族医药领域首部疾病分类国家标准，其出台标志 ...

1月26日医药板块强势吸金，一边是印度尼帕病毒病例引发对疫苗与创新药的关注，另一边是中国药企 出海大单不断，ADC、小核酸等领域频频"爆单"。行情背后，结构远比想象中清晰，该如何把握医药行 情中的"黄金主线"？请看机构最新研判。 综合来看，机构提示投资者可沿以下主线布局医药板块： 四是关注具有出海潜力或高股息防御属性的中药及药店板块，如佐力药业、东阿阿胶、益丰药房等。 1月26日医药板块资金流入明显，市场情绪在多重因素催化下呈现活跃态势。机构分析，一方面，行业 基本面的边际改善与政策端的支持形成共振；另一方面，海外疫情事件如印度尼帕病毒感染病例的出 现，也再次引发市场对疫苗、抗病毒药物及公共卫生防御体系的关注。此类事件往往能强化市场对医药 板块，尤其是创新药、疫苗及诊断领域的长期投资逻辑的信心。 风险提示：行业政策调整带来的预期变化；新药和器械在研发过程中，存在临床入组进度不确定、疗效 结果及安全性结果数据不确定等风险。以上观点均来自东吴证券、华鑫证券、中信建投、湘财证券、西 南证券近期公开的研究报告，不代表本平台立场，敬请投资者注意投资风险。 从近期机构观点来看，医药板块的结构性机会正得到进一步明确。创新药 ...

在国家大力推动科技创新与产业创新深度融合的背景下，为促进"十五五"期间阿胶产业高质量发展，1 月25日，中国农业大学—东阿阿胶产业创新研究院创新成果发布会隆重举行。发布会以"科技蓄势 生态 永续"为主题，系统展示了产业创新研究院在阿胶行业原料领域关键技术层面的阶段性成果，标志着东 阿阿胶正式开启"十五五"科技叙事的新篇章。 中国农业大学校长、产业创新研究院院长孙其信出席并讲话，东阿阿胶董事长程杰致辞。中国农业大学 副校长辛贤，内蒙古自治区阿拉善盟副盟长刘冲霄，中国农业大学人事处处长兼人才工作办公室主任、 产业创新研究院执行院长隋熠，中国农业大学理学院副院长、产业创新研究院副院长张振华，东阿阿胶 总裁孙金妮等出席。 中国农业大学经济管理学院研究员、产业创新研究院执行院长付文阁，中国农业大学动物科学技术学院 教授、产业创新研究院副院长马秋刚，中国农业大学食品科学与营养工程学院教授倪元颖，中国农业大 学生物学院教授吴森，中国农业大学食品科学与营养工程学院教授李兴民，中国农业大学营养与健康系 教授郭慧媛，东阿阿胶外部战略咨询专家李页瑞等发布相关研究成果。中国农业大学相关院系专家、教 授，新闻媒体代表，东阿阿胶管理团队 ...

Core Viewpoint - The "2026 Old Brand National Tide New Year Goods Fair" serves as a significant cultural and consumer event, showcasing traditional Chinese brands and promoting local products while enhancing consumer engagement through immersive experiences [1][2][3] Group 1: Event Overview - The fair, held at the Linyi International Expo Center, features nearly 200 old brand enterprises from 16 provinces, creating a vibrant cultural consumption atmosphere for the New Year [1] - The event includes five themed exhibition areas: "New Year's Eve Dinner," "Happy Reunion," "Visiting Friends and Relatives," "Langya Gifts," and "Traditional Folk Experience," highlighting various aspects of traditional New Year celebrations [1] Group 2: Consumer Engagement - Interactive experiences such as traditional paper-cutting, wood carving, and live cooking demonstrations attract significant visitor interest, enhancing the festive atmosphere [2] - The fair offers various consumer incentives, including limited-time discounts and gifts for purchases, effectively stimulating consumer enthusiasm and promoting immediate sales [2] Group 3: Cultural Significance - The event not only serves as a consumer fair but also plays a crucial role in promoting traditional Chinese culture and fostering innovation in domestic brands [3] - The fair runs from January 22 to January 26, providing an opportunity for consumers to engage with traditional crafts and experience the vibrant atmosphere of the New Year [3]

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [1] Core Views - The company is the largest OTC manufacturer in China, with a strong brand presence and a projected revenue compound annual growth rate (CAGR) of 7.5% from 2019 to 2024 [6][26] - The pharmaceutical manufacturing segment ranks second in the industry, while the pharmaceutical distribution segment ranks third [6][65] - The company has a robust pipeline of acquisitions to expand its business scope, particularly in traditional Chinese medicine and healthcare products [7][38] Summary by Sections Company Overview - China Resources Pharmaceutical Group Limited is a leading integrated pharmaceutical company, covering manufacturing and distribution of pharmaceuticals, healthcare products, and medical devices [20] - The company has a significant market presence, with a market capitalization of HKD 285.23 billion and a closing price of HKD 4.54 as of January 16, 2026 [1] Financial Performance - The company’s revenue for the first half of 2025 reached CNY 1,319 billion, with a year-on-year growth of 3% [26] - The distribution business accounted for approximately 80% of total revenue, with distribution revenue of CNY 1,045 billion, growing by 2% [26] - The pharmaceutical business generated CNY 218 billion in revenue, increasing its share from 15% in 2019 to 17% in the first half of 2025 [26] Pharmaceutical Manufacturing - The company produces 944 products, including traditional Chinese medicine, chemical drugs, biological products, and medical devices, covering a wide range of therapeutic areas [32] - The pharmaceutical business is expected to grow at a CAGR of 10.4% from 2022 to 2024 [36] Pharmaceutical Distribution - The company’s distribution revenue for the first half of 2025 was CNY 1,100 billion, ranking third in the industry, behind China National Pharmaceutical Group and Shanghai Pharmaceuticals [8][65] - The distribution model is evolving from traditional distribution to a dual approach of distribution and deep marketing [8] Profit Forecast and Valuation - The projected net profit attributable to ordinary shareholders for 2025-2027 is CNY 34.9 billion, CNY 37.6 billion, and CNY 40.5 billion, respectively, with growth rates of 4.0%, 7.9%, and 7.7% [9] - The report assigns a price-to-earnings (PE) ratio of 8.7x for 2026, suggesting a market value of HKD 353 billion, indicating a 24% upside potential from the current market value [8] Key Assumptions - The pharmaceutical business is expected to grow at rates of 4.1%, 6.0%, and 6.5% from 2025 to 2027 [12] - The distribution business is projected to grow at rates of 2.6%, 5.0%, and 5.3% during the same period [12] - The retail business is anticipated to grow at rates of 11.8%, 12.0%, and 12.0% from 2025 to 2027 [12]

Core Viewpoint - The company has publicly disclosed the list of candidates for the first phase of the restricted stock incentive plan, confirming that all candidates meet the necessary qualifications and legal requirements [1][2]. Group 1: Public Disclosure - The company conducted an internal public announcement of the list of candidates for the reserved grant of restricted stock from December 30, 2025, to January 9, 2026, involving 31 individuals [1]. - During the public announcement period, no objections were raised by any organization or individual regarding the list of candidates [1]. Group 2: Verification Opinions - The company's Board of Directors' Compensation and Assessment Committee verified that all candidates meet the qualifications stipulated by relevant laws and regulations, including the Company Law and Securities Law, as well as the company's internal regulations [1][2]. - The candidates do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares, ensuring compliance with the regulations [1].

Core Viewpoint - The company has publicly disclosed the list of reserved grant incentive objects for the first phase of its restricted stock incentive plan, confirming that all candidates meet the necessary qualifications and legal requirements [1][2][3]. Disclosure Situation - The company conducted an internal public announcement of the reserved grant incentive object list from December 30, 2025, to January 9, 2026, involving 31 individuals [1]. - During the public announcement period, no organization or individual raised any objections to the list of incentive objects [1]. Verification Opinions - The board's remuneration and assessment committee confirmed that all reserved grant incentive objects meet the qualifications stipulated by relevant laws and regulations, including the Company Law and Securities Law, and do not fall under any disqualifying conditions [2][3]. - The basic information regarding the reserved grant incentive objects is accurate, with no instances of falsehood or significant misunderstanding [3].

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-03 东阿阿胶股份有限公司 董事会薪酬与考核委员会关于第一期限制性股票激励计划 预留授予激励对象名单公示情况的说明及核查意见 本公司及董事会薪酬与考核委员会全体成员保证信息披露的内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 根据《中央企业控股上市公司实施股权激励工作指引》（以下简称《工作指 引》）、《上市公司股权激励管理办法》（以下简称《管理办法》）及东阿阿胶 股份有限公司（以下简称"公司"）《第一期限制性股票激励计划（草案二次修 订稿）》（以下简称《激励计划》）等有关规定，公司对第一期限制性股票激励 计划拟授予预留限制性股票的激励对象名单，在公司内部进行了公示。 公司董事会薪酬与考核委员会结合公示情况，对激励对象名单进行了核查， 相关公示情况及核查意见如下： 一、公示情况 公司于 2025 年 12 月 30 日至 2026 年 1 月 9 日，在公司内部对预留授予激励 对象名单进行了公示，人数为 31 人。 公司董事会薪酬与考核委员会根据《工作指引》《管理办法》《激励计划》 和《公司章程》等规定,结合对激励对象名单的审核结果及 ...